Communiqués Bicycle Therapeutics plc

Actions

BCYC

US0887861088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
3,380 ^USD	-5,06 %		-8,28 %	-52,26 %

28/09	Les actions européennes cotées aux États-Unis sous forme de certificats américains de dépôt commencent la semaine en légère baisse lundi	MT
25/09	Les actions européennes négociées aux États-Unis sous forme de certificats américains de dépôt (ADR) progressent légèrement vendredi, mais reculent sur la semaine	MT

Communiqués

30/07	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results	BU
21/05	Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting	BU
30/04	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results	BU
21/04	Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting	BU
20/04	Bicycle Therapeutics : April 2026 Corporate Presentation	PU
20/04	Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026	BU
18/03	Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026	BU
17/03	Bicycle Therapeutics : March 2026 Corporate Presentation	PU
17/03	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results	BU
03/02	Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline	BU
12/01	Bicycle Therapeutics : January 2026 Corporate Deck	PU
12/01	Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026	BU
16/12	Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline	BU
12/11	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference	BU
30/10/25	Bicycle Therapeutics : October 2025 Corporate Deck	PU
30/10/25	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results	BU
08/09/25	Bicycle Therapeutics Strengthens Board of Directors with New Appointments	BU
11/08/25	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results	AQ
08/08/25	Bicycle Therapeutics : August 2025 Corporate Deck	PU
08/08/25	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results	BU
02/07/25	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
03/06/25	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
22/05/25	Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting	BU
05/05/25	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
01/05/25	Bicycle Therapeutics : May 2025 Corporate Deck	PU